Results 151 to 160 of about 7,825,369 (248)

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. [PDF]

Ther Adv Neurol Disord
Oreja-Guevara C, Gómez-Estévez I, Agüado García L, Martín Martínez J, Gómez Gutiérrez M, Gascón Giménez F, Agüera Morales E, Meca-Lallana V, Barrero Hernández FJ, González Quintanilla V, Romero Pinel L, Delgado Gil V, Durán Ferreras E, Blasco Quílez R, Meca-Lallana J, Landete Pascual L, Aladro-Benito Y, Boyero Durán S, Gracia Gil J, Caminero Rodríguez AB, Cano Orgaz AT, Eichau Madueño S, Querol Pascual MR, Otano Martínez M, Alonso Torres AM, Calles Hernández C, López Real A, Ares Luque A, Lorenzo González JR, Gómez Vicente L, Díaz Sánchez M.   +30 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis. [PDF]

Int J Mol Sci
Uawithya E, Mytych JS, Muwenda I, Reidy M, Khan M, Mao-Draayer Y.   +5 more
europepmc   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

Mechanism study of an articular cartilage repair material and its forward‐looking test for space medicine

BMEMat, EarlyView.
The regeneration process following dLhCG engraftment progressed through four distinct and interconnected stages. dLhCG maintained its regenerative efficacy after 6 months of cosmic exposure, supporting its potential application in space medicine.
Xu Hu, Hang Yao, Zhen Zhang, Zhonglian Wu, Huiqun Zhou, Bangheng Liu, Liang Ma, Yulei Mu, Dong‐An Wang   +8 more
wiley   +1 more source

Radiotherapy Improves the Disability in Patients with Secondary Progressive Multiple Sclerosis. [PDF]

J Biomed Phys Eng, 2023
Ebrahimi HA, Larizadeh MH, Saba M, Jafarzadeh A.   +3 more
europepmc   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Engineering programmable peptide hydrogels for chronic refractory wounds: A mechanism‐driven framework

BMEMat, EarlyView.
To break the self‐perpetuating pathology of chronic wounds, we propose a mechanism‐driven engineering framework for peptide‐based hydrogels. This review elucidates a hierarchical strategy—from molecular design to intelligent, multi‐functional systems—that enables these programmable biomaterials to dynamically intervene in key pathological loops and ...
Xiaoyu Lv, Xinyi Chao, Jiamin Zhang, Jianfeng Liu   +3 more
wiley   +1 more source

Opsoclonus in Pediatric Patients: Differential Diagnosis and a Practical Approach to Evaluation

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Opsoclonus is an ocular dyskinesia characterized by involuntary, arrhythmic, multidirectional saccades. In pediatrics, opsoclonus is most commonly attributed to the rare neuroinflammatory disorder opsoclonus‐myoclonus‐ataxia syndrome (OMAS), typically considered a paraneoplastic syndrome associated with neural crest tumors. However, opsoclonus
Aubrey C. Reed, Supreet S. Randhawa, Jason H. Peragallo, Prabhumallikarjun Patil, Grace Gombolay, Varun Kannan   +5 more
wiley   +1 more source

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. [PDF]

Eur J Neurol
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree BAC, Ansari S, Meier DP, Karlsson G, Rouyrre N, Giovannoni G.   +11 more
europepmc   +1 more source